GSK Launches $10.6B All-Cash Tender Offer for Nuvalent at $124.00/Share; Board Recommends Acceptance
NUVL sits 73% above its 52-week low of $71.13.
Summary
Nuvalent's Board of Directors unanimously recommends shareholders accept GSK's $10.6 billion all-cash tender offer of $124.00 per share, which formally commenced today.
Key Events · M&A and Partnerships · NUVL
-
Definitive Merger Agreement
GlaxoSmithKline LLC (GSK) has launched an all-cash tender offer to acquire Nuvalent, Inc. for $124.00 per share, valuing the company at approximately $10.6 billion on a fully-diluted equity basis. This follows the merger agreement announced on June 9, 2026.
-
Significant Premium Offered
The offer price of $124.00 per share represents a 40% premium to Nuvalent's closing price on June 8, 2026, the last trading day before the merger announcement, and an 11% premium to the 52-week high as of that date.
-
Unanimous Board Recommendation
Nuvalent's Board of Directors unanimously recommends that shareholders accept the tender offer and tender their shares, based on the determination that the transaction is advisable and in the best interests of the company and its shareholders. This recommendation is supported by a fairness opinion from Centerview Partners LLC.
-
Equity Award Conversion
All outstanding Company Stock Options, Restricted Stock Units (RSUs), and Performance Stock Units (PSUs) will be cancelled at the effective time and converted into a right to receive cash consideration based on the offer price (minus the exercise price for options).
Analysis · NUVL · Life Sciences
This filing confirms the definitive merger agreement for GlaxoSmithKline (GSK) to acquire Nuvalent for approximately $10.6 billion in an all-cash tender offer. The offer price of $124.00 per share represents a substantial premium to Nuvalent's recent trading prices, including a 40% premium to the closing price before the announcement. This transaction provides immediate and certain cash value to shareholders, eliminating the inherent risks associated with Nuvalent's standalone commercialization efforts for its drug candidates. The unanimous board recommendation, supported by a fairness opinion, underscores the conviction that this is the best outcome for shareholders.
At the time of this filing, NUVL was trading at $123.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.62. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.